12.43

1.64% 0.20

Day One Biopharmaceuticals Inc (DAWN)

Overview News Price History Option Chain Financials Discussions Forecast

Day One Biopharmaceuticals Inc stock is traded at $12.43, with a volume of 738.31K. It is up +1.64% in the last 24 hours and up +1.55% over the past month. Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.

Previous Close:

$12.23

Open:

$12.38

24h Volume:

738.31K

Relative Volume:

0.78

Market Cap:

$1.25B

Revenue:

Net Income/Loss:

$-167.48M

P/E Ratio:

-6.3744

EPS:

-1.95

Net Cash Flow:

$-197.47M

1W Performance:

+1.39%

1M Performance:

+1.55%

6M Performance:

-12.46%

1Y Performance:

-15.73%

1-Day Range:

$12.19

$12.46

1-Week Range:

$11.65

$12.54

52-Week Range:

$11.13

$18.07

Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile

Name

Day One Biopharmaceuticals Inc

Sector

Healthcare (1169)

Industry

Biotechnology (678)

Phone

650 484-0899

Address

2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE

Employee

174

Twitter

Next Earnings Date

Latest SEC Filings

DAWN's Discussions on Twitter

Compare DAWN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DAWN Day One Biopharmaceuticals Inc	12.43	1.25B	0	-167.48M	-197.47M	-1.95
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-09-24	Reiterated	Needham	Buy
Aug-01-24	Upgrade	BofA Securities	Underperform → Buy
Apr-24-24	Reiterated	Needham	Buy
Apr-25-23	Downgrade	BofA Securities	Buy → Underperform
Feb-08-23	Initiated	CapitalOne	Overweight
Feb-03-23	Initiated	Oppenheimer	Perform
Dec-15-22	Initiated	H.C. Wainwright	Buy
Dec-14-22	Initiated	Needham	Buy
Dec-05-22	Initiated	Goldman	Buy
Dec-01-22	Initiated	BofA Securities	Buy

View All

Day One Biopharmaceuticals Inc Stock (DAWN) Latest News

Feb 21, 2025

Day One Biopharmaceuticals CEO sells shares for $144,130 By Investing.com - Investing.com Nigeria

Feb 21, 2025

Day one biopharmaceuticals general counsel sells $55,580 in stock - Investing.com

Feb 21, 2025

Day One Biopharmaceuticals CEO sells shares for $144,130 - Investing.com India

Feb 21, 2025

Day one biopharmaceuticals' COO York sells $52,278 in stock - Investing.com

Feb 21, 2025

Day one biopharmaceuticals general counsel sells $55,580 in stock By Investing.com - Investing.com UK

Feb 21, 2025

Feb 20, 2025

Day One Biopharmaceuticals (DAWN) Projected to Post Earnings on Monday - MarketBeat

Feb 20, 2025

TimesSquare Capital Management LLC Has $21.68 Million Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat

Feb 20, 2025

Feb 16, 2025

(DAWN) Trading Advice - Stock Traders Daily

Feb 16, 2025

Feb 14, 2025

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of "Buy" from Analysts - MarketBeat

Feb 14, 2025

Day One Bio's Talks With FDA Help Secure Glioma Drug Approval - Clinical Leader

Feb 14, 2025

Feb 13, 2025

Does Day One Biopharmaceuticals (DAWN) Have the Potential to Rally 193.16% as Wall Street Analysts Expect? - Yahoo Finance

Feb 13, 2025

New Strong Buy Stocks for February 13th - Yahoo Finance

Feb 13, 2025

The Goldman Sachs Group Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $43.00 - MarketBeat

Feb 13, 2025

Feb 11, 2025

Day One Biopharmaceuticals to Host Conference Call to Discuss Q4 and Full-Year 2024 Financial Results and Corporate Progress - Nasdaq

Feb 11, 2025

Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025 - GlobeNewswire

Feb 11, 2025

Day One (DAWN) Q4 Earnings Call: Key Strategic Updates Coming February 25 - StockTitan

Feb 11, 2025

Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Lowered to $43.00 at The Goldman Sachs Group - Defense World

Feb 11, 2025

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of “Buy” by Analysts - Defense World

Feb 11, 2025

Feb 07, 2025

Day One Bio Aims To Shorten the Time Gap On Cancer Treatments For Kids - Life Science Leader Magazine

Feb 07, 2025